相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vaccines and biologics
Isabel Ferreira et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions
L. Adelzadeh et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting
Christen Lykkegaard Andersen et al.
PLOS ONE (2014)
Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0
Tatiana Cobo-Ibanez et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Treatment With Anti-Tumor Necrosis Factor Biologic Agents in Human T Lymphotropic Virus Type I-Positive Patients With Rheumatoid Arthritis
Kunihiko Umekita et al.
ARTHRITIS CARE & RESEARCH (2014)
Detectable Anti-Infliximab Antibodies in Children Treated with Infliximab for Rheumatic Diseases
Florence A. Aeschlimann et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
Fabrizio Cantini et al.
JOURNAL OF RHEUMATOLOGY (2014)
Association Between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
Kevin L. Winthrop et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Progressive Multifocal Leukoencephalopathy Associated With Immunosuppressive Therapy in Rheumatic Diseases
Eamonn S. Molloy et al.
ARTHRITIS AND RHEUMATISM (2012)
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
Fabiola Atzeni et al.
AUTOIMMUNITY REVIEWS (2012)
Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
Evangelista Sagnelli et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Progressive multifocal leukoencephalopathy in autoimmune diseases
Elisabeth Palazzo et al.
JOINT BONE SPINE (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Daniel I. Swerdlow et al.
LANCET (2012)
Management of rheumatic disease with comorbid HBV or HCV infection
Dimitrios Vassilopoulos et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Screening of tuberculosis before biologics
N. Mrozek et al.
MEDECINE ET MALADIES INFECTIEUSES (2012)
Assessing the safety of biologic agents in patients with rheumatoid arthritis
Andrea Rubbert-Roth
RHEUMATOLOGY (2012)
Overview of safety of non-biologic and biologic DMARDs
Eric M. Ruderman
RHEUMATOLOGY (2012)
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease
Tauseef Ali et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Current treatment of hepatitis C-associated rheumatic diseases
Clodoveo Ferri et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Epidemiological aspects and world distribution of HTLV-1 infection
Antoine Gessain et al.
FRONTIERS IN MICROBIOLOGY (2012)
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy
Joung-Liang Lan et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
Xavier Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety
Yukiko Komano et al.
JOURNAL OF RHEUMATOLOGY (2011)
Safety of biologic therapy in rheumatoid arthritis
Robert S. Woodrick et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis
Michael A. Lane et al.
MEDICINE (2011)
Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis
Wassila Amari et al.
RHEUMATOLOGY (2011)
The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
RHEUMATOLOGY (2011)
Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
Alexandra M. G. Brunasso et al.
RHEUMATOLOGY (2011)
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label
Candido Diaz-Lagares et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
J. D. Greenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Demyelinating events in rheumatoid arthritis after drug exposures
Sasha Bernatsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
Ignacio Garcia-Doval et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I. Solovic et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Initiation of rheumatoid arthritis treatments and the risk of serious infections
Carlos G. Grijalva et al.
RHEUMATOLOGY (2010)
Infections in polymyositis and dermatomyositis: analysis of 192 cases
I-Jung Chen et al.
RHEUMATOLOGY (2010)
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
C. Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
J. Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Progressive Multifocal Leukoencephalopathy A National Estimate of Frequency in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Eamonn S. Molloy et al.
ARTHRITIS AND RHEUMATISM (2009)
Risk of Tuberculosis Is Higher With Anti-Tumor Necrosis Factor Monoclonal Antibody Therapy Than With Soluble Tumor Necrosis Factor Receptor Therapy The Three-Year Prospective French Research Axed on Tolerance of Biotherapies Registry
F. Tubach et al.
ARTHRITIS AND RHEUMATISM (2009)
Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis
Jay R. McDonald et al.
CLINICAL INFECTIOUS DISEASES (2009)
Reactivation of Hepatitis B
Jay H. Hoofnagle
HEPATOLOGY (2009)
Does the Implementation of an Interferon-γ Release Assay in Lieu of a Tuberculin Skin Test Increase Acceptance of Preventive Therapy for Latent Tuberculosis Among Healthcare Workers?
Rajiv Sahni et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF-α Agents
Anja Strangfeld et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab
Penny Lovell English et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: Update
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2009)
Use of Tumor Necrosis Factor-alpha-blocking Agents in Hepatitis B Virus-positive Patients: Reports of 3 Cases and Review of the Literature
Stefania Zingarelli et al.
JOURNAL OF RHEUMATOLOGY (2009)
Latent Tuberculosis Diagnosis in Children by Using the QuantiFERON-TB Gold In-Tube Test
Jennifer Lighter et al.
PEDIATRICS (2009)
Predictors of major infections in systemic lupus erythematosus
Guillermo Ruiz-Irastorza et al.
ARTHRITIS RESEARCH & THERAPY (2009)
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action
Angelique N. Collamer et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease
E. J. Cepeda et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Autoimmune diseases induced by TNF-targeted therapies -: Analysis of 233 cases
Manuel Ramos-Casals et al.
MEDICINE (2007)
Progressive multifocal leukoencephalopathy in rheumatic diseases - Evolving clinical and pathologic patterns of disease
Leonard H. Calabrese et al.
ARTHRITIS AND RHEUMATISM (2007)
Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease
Manal F. Abdelmalek et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Tumor necrosis factor and tuberculosis
Philana Ling Lin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2007)
Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review
Matthew E. Falagas et al.
CLINICAL RHEUMATOLOGY (2007)
Use of infliximab to treat psoriatic arthritis in HIV-positive patients
Jeremie Sellam et al.
JOINT BONE SPINE (2007)
Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions
Gillian C. de Gannes et al.
ARCHIVES OF DERMATOLOGY (2007)
Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
Soko Setoguchi et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
E Baecklund et al.
ARTHRITIS AND RHEUMATISM (2006)
Granulomatous lung disease occurring during etanercept treatment
K Phillips et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
Immunology of cutaneous vasculitis associated with both etanercept and infliximab
MD Srivastava et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2005)
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study
NN Zein
JOURNAL OF HEPATOLOGY (2005)
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
M De Bandt et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL)
DL Mann et al.
CIRCULATION (2004)
Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab
U Bartke et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Anti-TNF-α-induced systemic lupus syndrome
M Debandt et al.
CLINICAL RHEUMATOLOGY (2003)
Predictors of infection in rheumatoid arthritis
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis
BJ Fessler
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2002)
Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis
DM Aboulafia et al.
MAYO CLINIC PROCEEDINGS (2000)
Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases
LB Brydak et al.
VACCINE (2000)
分享论文
